Kaposi Sarcoma Market to reach a value of US$143.2 mn by

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
21
Kaposi Sarcoma Market to reach a value of US$143.2 mn by 2024, Says TMR

Albany, NY, Aug. 14, 2018 (GLOBE NEWSWIRE) -- According to the market intelligence study by Transparency Market Research, the global Kaposi sarcoma market was worth US$118.5 mn in 2015 and is anticipated to reach a value of US$143.2 mn by the end of 2024. The market is predicted to register a steady 2.20% CAGR between 2016 and 2024.

Presence of Leading Players to Drive North America Kaposi Sarcoma Market

The global market for Kaposi sarcoma has been categorized on the basis of geography into Latin America, North America, Europe, Asia Pacific, and the Middle East and Africa. Among these, North America led the global market in the last few years and is likely to remain in the similar position in the coming few years. The presence of a large number of leading players and the increasing costs of drugs are some of the major factors that are estimated to enhance the growth of the North America market in the next few years. In addition to this, the easy availability of advanced drugs and the technologically advanced healthcare are some of the other factors that are predicted to enhance the growth of the market in the near future. Furthermore, the Middle East and Africa is estimated to witness a healthy growth in the near future.

Request to View Sample of Report - https://www.transparencymarketresearch.com/sa...ep_id=3354

The global Kaposi sarcoma market has been categorized on the basis of treatments into chemotherapy, immunotherapy, and antiretroviral therapy. Among these, the antiretroviral therapy segment is expected to account for a major share of the overall market in the next few years. The rising incidence rate of AIDS-associated Kaposi sarcoma is one of the key factors predicted to enhance the growth of the market in the coming few years. Furthermore, the rising preference for this treatment and the high cost of treatment are some of the other factors that are predicted to enhance the growth of this segment in the next few years.

Request PDF Brochure of Report: https://www.transparencymarketresearch.com/sa...ep_id=3354

Rising Cases of Cancer to Encourage Growth of Kaposi Sarcoma Market

The increasing procedures for organ transplants and the rising incidence of cancer are the key factors that are projected to encourage the growth of the global Kaposi sarcoma market in the next few years. Furthermore, the rising cases of HIV/AIDS related to Kaposi sarcoma is another key factor, which is likely to accelerate the growth of the overall market in the next few years. In addition to this, the technological advancements in the healthcare sector and the introduction of new drugs for Kaposi sarcoma are projected to enhance the growth of the Kaposi sarcoma market in the next few years.

Request for Discount on This Report: https://www.transparencymarketresearch.com/sa...ep_id=3354

The global market for Kaposi sarcoma is highly consolidated in nature with two players holding a massive share of the market, states a new market intelligence study that’s has been recently published by Transparency Market Research. In 2015, the two leading players, namely Merck & Co. Inc. and Johnson & Johnson held a share of around 50% of the global market and is projected to remain in the similar situation in the next few years. The rising research and development activities in this field and the technological advancements are some of the major factors that are anticipated to enhance the growth of the global Kaposi sarcoma market in the coming few years. In addition to this, the increasing mergers and acquisitions and strategic collaboration is further anticipated to accelerate the growth of the overall market in the next few years.

Read Press Release : https://www.transparencymarketresearch.com/pr...market.htm

This information is based on the findings of a research report published by Transparency Market Research (TMR), titled “Kaposi Sarcoma Market (Treatment – Chemotherapy (Liposomal Anthracyclines, Alkaloids), Immunotherapy, HAART); Distribution Channel – Hospitals, Cancer Research Institutes, Multispecialty Clinics,Ambulatory Surgical Centers) – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 – 2024.”

More Trending Reports by Transparency Market Research -

Allergy Immunotherapy Market : https://www.transparencymarketresearch.com/al...arket.html

Cancer Immunotherapy Market: https://www.transparencymarketresearch.com/ca...arket.html

Key Takeaways:

  • The rising incidence of cancer is one of the key factors encouraging the growth of the Kaposi sarcoma market in the next few years.
  • The rising level of competition and the increasing focus on development of new products are predicted to enhance the growth of the market in the near future.

About TMR

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Contact 

Mr. Nachiket Ghumare Transparency Market Research State Tower 90 State Street, Suite 700, Albany, NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free: 866-552-3453 Email : sales@transparencymarketresearch.com Website: http://www.transparencymarketresearch.com Research Blog: http://theglobalhealthnews.com/

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 3

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 6

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 3

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 10

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 6

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading

Top 5 Most Recently Viewed Articles

Microbot Medical Secures $13 Million in Recent Offering

Updated Category News Views 92

Microbot Medical Makes Strategic Move with $13 Million Offering Microbot Medical Inc. (NASDAQ: MBOT) has recently taken an important step to elevate its operations by entering into definitive agreements to sell 6,103,289 shares of its common stock at a price of $2.13 per share. This registered direct offering, priced at-the-market under Nasdaq rules, underscores the...

Continue Reading
Evolv Technologies Faces Class Action Lawsuit: Know Your Rights

Updated Category News Views 651

Understanding the Evolv Technologies Holdings Class Action Recent developments have raised significant concerns among shareholders of Evolv Technologies Holdings, Inc. (NASDAQ: EVLV). A class action lawsuit is currently in progress, prompting investors to scrutinize the implications of false statements made by the company. The allegations revolve around misleading...

Continue Reading
Rhino Rescue Unveils Innovative First Aid Kits for Adventurers

Updated Category News Views 117

Rhino Rescue Launches Innovative Products for Outdoor Safety Rhino Rescue has made a remarkable stride in enhancing outdoor safety with its new lineup of first aid kits targeted towards adventurers and everyday users alike. The release of the Rhino Rescue Mini First Aid Kit, along with home and camping-specific options, marks an exciting development in the company’s...

Continue Reading
RUSH's 2026 Tour: Celebrating Legacy and New Beginnings

Updated Category News Views 258

RUSH's 2026 Tour: A Celebration of Music and Legacy Geddy Lee and Alex Lifeson are set to celebrate over 50 years of RUSH's musical journey as they announce a special headline tour for 2026, named the Fifty Something Tour. This tour not only commemorates the incredible music and legacy of RUSH, but also pays tribute to their late drummer and lyricist Neil Peart, whose...

Continue Reading
BioSyent Inc. Announces Quarterly Dividend for Shareholders

Updated Category News Views 132

BioSyent Inc. Announces Quarterly Dividend for Shareholders MISSISSAUGA, Ontario — BioSyent Inc. (TSX Venture: RX) is thrilled to communicate that its Board of Directors has approved a quarterly dividend of $0.05 per common share. This dividend will be paid in Canadian Dollars on a specified date to shareholders who are on record, enhancing the company's ongoing...

Continue Reading